|
- OnCore - Login
Support Links Chrome Firefox Safari Edge View Versions © 2026 Advarra, Inc
- Huntsman Cancer Institute Clincial Trials
To search for a clinical trial (protocol), use any or all of the search fields: Select from drop down lists or type search criteria in any of the text fields Browse by Physician or Drug, use the magnification icon to the left or above the field
- Huntsman Cancer Institute Clinical Trials
SIP Version 14 0 0 010 Copyright © 2001-2020 Forte Research Systems, Inc all rights reserved
- Version Date: 10 14 21 Protocol No. HCI IRB # 145008
Objectives The overall objective of this research proposal is to provide a new treatment-assessment paradigm for MRgFUS breast cancer ablation therapy Utilizing advanced in vivo MRI-to-histopathology image registration and supervised deep learning methods, we will develop and validate a non-contrast imaging biomarker that can accurately predict tissue viability during breast MRgFUS treatments
- Version Date: 4 17 15 Protocol No. HCI IRB # 71940
Objectives To determine the maximum tolerated dose for stereotactic radiosurgery (SRS) treatment for patients with 1-5 brain metastases treated with SRS as the first line therapy for their CNS disease
- Version Date: 5 22 19 Protocol No. HCI IRB # 122217
Inclusion Criteria **HCI WILL NOT HAVE PATIENTS <18 YEARS OF AGE** Inclusion Criteria Subjects who meet the following criteria will be eligible to participate in the LTFU study: 1 All adult and pediatric subjects who received at least one GM T cells infusion in a previous Celgene sponsored or Celgene alliance partner sponsored study, and have discontinued, or completed the post-treatment
- Version Date: 4 23 21 Protocol No. HCI IRB # 143005
Objectives Primary Objectives For Escalation Phase: Evaluate safety, tolerability and recommended phase 2 dose (RP2D) of DS-8201a in combination with AZD6738 in advanced solid tumors with HER2 expression For Expansion Phase: Assess differential pharmacodynamic (PD) profile of tumor tissue (DNA damage repair) between Top1 inhibition and dual inhibition of Top1 and ATR in patients with
- Version Date: 7 15 17 Protocol No. HCI IRB # 88405
Objectives Our over-arching study goal is to identify germline variants and biomarkers involved in risk or prognosis of hematological malignancies (HMs) Four designs provide a framework for the research: (1) genealogy-based; (2) pedigree-based; (3) case-control; and (4) case-only
|
|
|